The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC).
 
Meredith MI Freeman
No Relationships to Disclose
 
Ellen Jaeger
No Relationships to Disclose
 
Jason Zhu
Consulting or Advisory Role - Bayer; NGM Biopharmaceuticals
Travel, Accommodations, Expenses - UroToday
 
Audrey Phone
No Relationships to Disclose
 
Roberto Nussenzveig
Consulting or Advisory Role - Tempus
 
Sydney Caputo
No Relationships to Disclose
 
Deepak Ravindranathan
No Relationships to Disclose
 
Jodi Lyn Layton
No Relationships to Disclose
 
Lakshminarayanan Nandagopal
Honoraria - AstraZeneca
 
Adam Kessel
No Relationships to Disclose
 
Arpita Desai
Consulting or Advisory Role - Dendreon
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Nektar
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Arnab Basu
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Umang Swami
No Relationships to Disclose
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Clovis Oncology; Eisai; Sanofi; Targeted Oncology
Speakers' Bureau - Bayer; Merck; Sanofi; Sanofi/Aventis
Research Funding - Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (I); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Eisai; Janssen; Medivation/Astellas; Merck; Sanofi
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Earle F Burgess
Stock and Other Ownership Interests - Arvinas; Becton Dickinson; Calithera Biosciences; Clovis Oncology; Corvus Pharmaceuticals; Exelixis; Gilead Sciences; Macrogenics; Medtronic; Merus NV
Honoraria - Bayer; Exelixis; Merck; Myovant Sciences
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - AstraZeneca
Research Funding - Astellas Pharma; Pfizer
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)